Questões de Concurso
Sobre advérbios e conjunções | adverbs and conjunctions em inglês
Foram encontradas 581 questões
City hall braces for busy marriage day
If love is all you need, you’ll want for nothing in New York Thursday.
The folks who hand out marriage licenses are bracing for what could be their busiest day ever as Valentine’s Day romantics head to the aisle.
“When we are really busy, we have a second chapel we can open,” said First Deputy City Clerk Michael McSweeney. “We are preparing to do that. We’re expecting a lot of couples.”
City Hall’s unofficial record of 318 weddings on that date was set on Valentine’s Day 2002 - also on a Thursday.
And love is definitely in the air Thursday.
Melanie and Joseph Castine married on Valentine’s Day 10 years ago. Today, they’re renewing their vows in the same venue - the Empire State Building.
The couple, who recently moved from Roosevelt Island to Philadelphia, won a letter-writing competition with Brides.com to become one of 14 pairs tying the knot in the iconic building.
“Valentine’s Day is just the perfect day to do it,” said Melanie Castine, who, with her hubby, has been at the skyscraper every year to mark their anniversary.
“Everywhere you go in Manhattan, you can see the Empire State Building. It’s a constant reminder of our marriage. We call it our chapel in the sky.”
Meanwhile, love is being put on ice at one of the city’s most romantic spots.
Rockefeller Center is preparing to clear its rink at 8 p.m for a skater planning to get down on one knee for a surprise engagement.
“It’s a big surprise for her, but we’re sure it’s going to be extremely romantic,” a rink spokeswoman said.
(Available from: http://www.nydailynews.com/news/2008/02/14/2008-02-14 city hall braces for busy marriage day-1.html cited: 14 Feb. 2008)
Oil is the largest source of liquid fuel and, in spite of attempts to develop synthetic fuels, world consumption of oil
products in increasing.
The oil industry is not much more than a hundred years old. It began when the first oil well was drilled in 1859. In the
early days, oil was used to light houses because there was no electricity and gas was very scarce. Later, people began to use oil
for heating too.
Most industries use machinery to make things. Every machine needs oil in order to run easily. Even a small clock or watch
needs a little oil from time to time.
The engines of many machines use oil fuels petrol, kerosene or diesel. Cars, buses, trucks, tractors, and small aircraft use
petroleum chemicals: synthetic rubber, plastics, synthetic fiber materials for clothes and for the home, paints, materials which
help to stop rust, photographic materials, soap and cleaning materials (detergents), drugs, fertilizers for farms and gardens, food
containers, and may others.
In 1900 the world’s oil production was less than 2 million tons a year. Today the oil industry is one of the world’s largest
and most important suppliers of raw materials.
By Jonathan Weisman Washington Post Staff Writer Friday, November 4, 2005; A01
The Senate approved sweeping deficit-reduction legislation last night that would save about $35 billion over the next five years by cutting federal spending on prescription drugs, agriculture supports and student loans, while clamping down on fraud in the Medicaid program. The measure would also open Alaska's Arctic National Wildlife Refuge to oil drilling, a long-sought goal of the oil industry that took a major step forward after years of political struggle. A bipartisan effort to strip the drilling provision narrowly failed. The Senate bill, which passed 52 to 47, is the first in nearly a decade to tackle the growth of entitlement spending, the part of the federal budget that rises automatically based on set formulas and population changes. It would shave payments to some farmers by 2.5 percent, while eliminating a major cotton support program and trimming agriculture conservation spending. A proposal to limit payments to rich farmers failed yesterday. The measure passed largely along party lines, with only two Democrats voting for it and five Republicans voting against it. Yesterday's action is part of an effort by congressional Republicans to demonstrate fiscal discipline after widespread complaints of profligate spending on Capitol Hill. many Democrats and some moderate Republicans are concerned that the effort may go too far, prominent Republicans in the Senate and House said the cuts were necessary to slow the rate of spending and control a deficit projected to total $314 billion by the end of the fiscal year. During a speech yesterday, former House majority leader Tom Delay (R-Tex) repeatedly apologized for excessive spending by Congress, including recent highway legislation that was with lawmakers’ pet projects. After noting that House Republicans have voted to cut taxes every year since winning the majority in 1994, DeLay acknowledged, “Our record on spending has not been as consistent, ______ .”
(Adapted from washingtonpost.com)
Na questão, a palavra que preenche corretamente a lacuna é
They _________________ walk along the stream. They frequently do that.
Your answers to questions 33 to 37 must be based
on the text below, which is entitled "Young, liberal
and in command":
Young, liberal and in command
Source: www.economist.co.uk
April 16, 2004 (Adapted)
On Thursday April 15th, the challengers won a
crucial battle in their bid to overturn South Korea's
conservative, elitist and business-driven political
system. . (1) the country's voters . (1.1) able to
choose their leaders freely since the late 1980s, many
of them, especially younger ones, still consider their
brand of democracy to be corrupt, outdated and unfair.
Many of the discontented admit . (2) enjoyed the
comforts that decades of market-friendly policies and
high growth have delivered. But they resent the . (3)
and . (3.1) dominance of giant family-controlled
business conglomerates, known as chaebol. Their
feelings towards the United States, a crucial ally, range
from ambivalent to hostile, and they would rather . (4)
with North Korean threats by placating its prickly regime
than by standing up to it. And now, they have convinced
mainstream voters to let them . (5) the country for the
next four years.
Analyze the following grammatical alternatives in order
to choose the appropriate one to fill in each of the
numbered gaps:
The hard cell
Thanks to politics, stem cell research in the United States is suffering. But not so in Sweden, which is poised to capture what could be the biggest new market to hit biotech in a decade.
By Stephan Herrera
February 13, 2003
New York, January 1, 2006:
Sweden announces that one of its biotechnology companies is the first in the world to enter clinical trials with a new drug that could cure Alzheimer's disease. Four years ago this type of research was all but stopped in the United States by political and ethical questions − which is ...61... Sweden now seems in the best position to capture a $25 billion market.
Any day now, the U.S. Congress is expected to pass a sweeping new law that could dramatically inhibit researchers from working with stem cells taken from human embryos. Such cells, which can be used to grow a whole host of new cells and organs, could fundamentally change the way we treat heretofore intractable maladies like Alzheimer's disease, Parkinson's disease, cancer, stroke, liver failure, and heart disease. The only problem is that these cells by definition are derived from human embryos, many of which are cloned or come from unused fetuses collected at fertility clinics. The argument, from a certain segment of the American political spectrum, is that ...62... methods are morally wrong. They are ...63... a form of abortion or an activity that could eventually lead to human cloning.
Those working in stem cell research say the short-term effect of the legislation will be to further chill all forms of scientific inquiry and commercialization efforts in the field. Entrepreneurs and investors are already eschewing such research − in large part because of the additional uncertainty and risk that politics introduce.
Of the nearly 50 private stem cell companies in the United States, only a handful are still viable. Meanwhile, across the Atlantic, Sweden has avoided many of the political and ethical quagmires surrounding this type of research. It currently has 40 private stem cell companies, a number that's growing. Sweden's leading research universities have 32 percent of the world's stem cell inventory, close on the heels of the United States' 35 percent.
Sweden, say analysts, is now in the best position to
capture a worldwide market for drugs based on stem cell
therapies that could grow to $25 billion in the next three to five
years − nearly equal to the whole biotech industry at present.
This estimate doesn't even address the market for stem cells
capable of repairing damaged vital organs like the brain, heart,
and kidneys. If the United States offers an object lesson of what
can happen when scientific inquiry and investment capital fall victim to politics, Sweden and its leading stem cell startup,
NeuroNova, offer the opposite example. How odd that the
United States, which for generations has been the envy of the
world for its progressive views of science and commercialization,
should now have a biomedical climate chillier than a Swedish
winter.
One company feeling a lot of pain is StemCells, which at first glance seems to have it all: founding scientists include Stanford's Dr. Weissman and Fred Gage of the Salk Institute in La Jolla, California. An equally well-regarded expert in the treatment of Alzheimer's, Dr. Gage spent five years in Sweden as a researcher and now sits on a national committee on stem cell research there. The firm's chairman is Roger Perlmutter, Amgen's head of research.
Yet over the past two years, none of management's efforts to help investors and even critics reconsider the stem cell field have worked. At press time, the stock was thinly traded and sitting in the neighborhood of 50 cents. With less than $15 million in cash, the company likely won't exist at this time next year. (CEO Martin McGlynn, who joined the firm in January 2001, would not talk to Red Herring, despite repeated efforts.)
Some observers on Wall Street are asking, If StemCells can't make it, who can? Geron, the only other publicly held stem cell firm to speak of, is in a fix, too. The company's stock price is also moribund, at $3.85 per share. Thanks to some capital infusions a few years ago, when money came easy, Geron still has $40 million on hand, but by the end of next year, that too will likely be gone. Once a media darling, Geron focuses on diagnostic tests and drugs derived from stem cells, a strategy that's not going well. For the nine months ended last September, revenue fell 68 percent to $955,000 and net loss widened 18 percent to $26.7 million. The company's financials were also hit hard after it terminated an agreement with Pharmacia and acquired research technology from Lynx Therapeutics, which Geron bought in a desperate attempt to be seen as something more than just a stem cell company.
The situation is quite different, however, for Sweden's NeuroNova, which has 30 academic partners and a staff of 20. NeuroNova is working on ways to inject stem cells into the human brain to trigger a process called neurogenesis (the growth of new neural cells), which could combat diseases like Parkinson's, Alzheimer's, and even schizophrenia.
If NeuroNova is the first to develop a drug capable of
treating one of several central nervous system disorders − by far
the most lucrative after heart disease products − it will have
done so not because it raised more money or got more media
buzz than the rest. It will have succeeded because the science
is solid, and academe, government, and the investment
community are supportive. Meanwhile, the United States will
look on with envy and wonder how it, a country known for its
entrepreneurial innovation, ever got so short-sighted.
(Adapted from
http://www.redherring.com/investor/2003/02/biotech021303.html)
The hard cell
Thanks to politics, stem cell research in the United States is suffering. But not so in Sweden, which is poised to capture what could be the biggest new market to hit biotech in a decade.
By Stephan Herrera
February 13, 2003
New York, January 1, 2006:
Sweden announces that one of its biotechnology companies is the first in the world to enter clinical trials with a new drug that could cure Alzheimer's disease. Four years ago this type of research was all but stopped in the United States by political and ethical questions − which is ...61... Sweden now seems in the best position to capture a $25 billion market.
Any day now, the U.S. Congress is expected to pass a sweeping new law that could dramatically inhibit researchers from working with stem cells taken from human embryos. Such cells, which can be used to grow a whole host of new cells and organs, could fundamentally change the way we treat heretofore intractable maladies like Alzheimer's disease, Parkinson's disease, cancer, stroke, liver failure, and heart disease. The only problem is that these cells by definition are derived from human embryos, many of which are cloned or come from unused fetuses collected at fertility clinics. The argument, from a certain segment of the American political spectrum, is that ...62... methods are morally wrong. They are ...63... a form of abortion or an activity that could eventually lead to human cloning.
Those working in stem cell research say the short-term effect of the legislation will be to further chill all forms of scientific inquiry and commercialization efforts in the field. Entrepreneurs and investors are already eschewing such research − in large part because of the additional uncertainty and risk that politics introduce.
Of the nearly 50 private stem cell companies in the United States, only a handful are still viable. Meanwhile, across the Atlantic, Sweden has avoided many of the political and ethical quagmires surrounding this type of research. It currently has 40 private stem cell companies, a number that's growing. Sweden's leading research universities have 32 percent of the world's stem cell inventory, close on the heels of the United States' 35 percent.
Sweden, say analysts, is now in the best position to
capture a worldwide market for drugs based on stem cell
therapies that could grow to $25 billion in the next three to five
years − nearly equal to the whole biotech industry at present.
This estimate doesn't even address the market for stem cells
capable of repairing damaged vital organs like the brain, heart,
and kidneys. If the United States offers an object lesson of what
can happen when scientific inquiry and investment capital fall victim to politics, Sweden and its leading stem cell startup,
NeuroNova, offer the opposite example. How odd that the
United States, which for generations has been the envy of the
world for its progressive views of science and commercialization,
should now have a biomedical climate chillier than a Swedish
winter.
One company feeling a lot of pain is StemCells, which at first glance seems to have it all: founding scientists include Stanford's Dr. Weissman and Fred Gage of the Salk Institute in La Jolla, California. An equally well-regarded expert in the treatment of Alzheimer's, Dr. Gage spent five years in Sweden as a researcher and now sits on a national committee on stem cell research there. The firm's chairman is Roger Perlmutter, Amgen's head of research.
Yet over the past two years, none of management's efforts to help investors and even critics reconsider the stem cell field have worked. At press time, the stock was thinly traded and sitting in the neighborhood of 50 cents. With less than $15 million in cash, the company likely won't exist at this time next year. (CEO Martin McGlynn, who joined the firm in January 2001, would not talk to Red Herring, despite repeated efforts.)
Some observers on Wall Street are asking, If StemCells can't make it, who can? Geron, the only other publicly held stem cell firm to speak of, is in a fix, too. The company's stock price is also moribund, at $3.85 per share. Thanks to some capital infusions a few years ago, when money came easy, Geron still has $40 million on hand, but by the end of next year, that too will likely be gone. Once a media darling, Geron focuses on diagnostic tests and drugs derived from stem cells, a strategy that's not going well. For the nine months ended last September, revenue fell 68 percent to $955,000 and net loss widened 18 percent to $26.7 million. The company's financials were also hit hard after it terminated an agreement with Pharmacia and acquired research technology from Lynx Therapeutics, which Geron bought in a desperate attempt to be seen as something more than just a stem cell company.
The situation is quite different, however, for Sweden's NeuroNova, which has 30 academic partners and a staff of 20. NeuroNova is working on ways to inject stem cells into the human brain to trigger a process called neurogenesis (the growth of new neural cells), which could combat diseases like Parkinson's, Alzheimer's, and even schizophrenia.
If NeuroNova is the first to develop a drug capable of
treating one of several central nervous system disorders − by far
the most lucrative after heart disease products − it will have
done so not because it raised more money or got more media
buzz than the rest. It will have succeeded because the science
is solid, and academe, government, and the investment
community are supportive. Meanwhile, the United States will
look on with envy and wonder how it, a country known for its
entrepreneurial innovation, ever got so short-sighted.
(Adapted from
http://www.redherring.com/investor/2003/02/biotech021303.html)
Conheça nossos planos